FULGENT GENETICS, INC. Current Federal Tax Expense (Benefit)
FULGENT GENETICS, INC. (FLGT) reported Current Federal Tax Expense (Benefit) of -$6.47 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-02-27
- FULGENT GENETICS, INC. current federal tax expense (benefit) for fiscal 2025 was -$6.47M.
- FULGENT GENETICS, INC. current federal tax expense (benefit) for fiscal 2024 was -$2.44M.
- FULGENT GENETICS, INC. current federal tax expense (benefit) for fiscal 2023 was -$5.59M, a 117.95% decline from fiscal 2022.
- FULGENT GENETICS, INC. current federal tax expense (benefit) for fiscal 2022 was $31.14M, a 76.39% decline from fiscal 2021.
| Period end | Current Federal Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$6.47M 10-K · filed 2026-02-27 |
| 2024-12-31 | -$2.44M 10-K · filed 2026-02-27 |
| 2023-12-31 | -$5.59M 10-K · filed 2026-02-27 |
| 2022-12-31 | $31.14M 10-K · filed 2025-02-28 |
| 2021-12-31 | $131.91M 10-K · filed 2024-02-28 |
| 2020-12-31 | $53.79M 10-K · filed 2023-02-28 |
| 2019-12-31 | $5.00K 10-K · filed 2022-02-28 |
| 2017-12-31 | -$599.00K 10-K · filed 2019-03-22 |
| 2016-12-31 | $616.00K 10-K · filed 2018-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |